1. Others
  2. Others
  3. Benserazide hydrochloride

Benserazide hydrochloride (Synonyms: Serazide; Ro 4-4602)

Cat. No.: HY-B0404A Purity: 99.41%
Handling Instructions

Benserazide hydrochloride (Serazide) is commonly used in Parkinson's disease and is an inhibitor of peripheral aromatic L-amino acid decarboxylase (AADC).

For research use only. We do not sell to patients.

Benserazide hydrochloride Chemical Structure

Benserazide hydrochloride Chemical Structure

CAS No. : 14919-77-8

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply Now  
Solution
10 mM * 1 mL in DMSO USD 55 In-stock
Estimated Time of Arrival: December 31
Solid + Solvent
10 mM * 1 mL
ready for reconstitution
USD 55 In-stock
Estimated Time of Arrival: December 31
Solid
500 mg USD 50 In-stock
Estimated Time of Arrival: December 31
1 g USD 72 In-stock
Estimated Time of Arrival: December 31
5 g USD 240 In-stock
Estimated Time of Arrival: December 31
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products

Publications Citing Use of MCE Benserazide hydrochloride

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Benserazide hydrochloride (Serazide) is commonly used in Parkinson's disease and is an inhibitor of peripheral aromatic L-amino acid decarboxylase (AADC)[1].

In Vitro

Benserazide hydrochloride (BH) and Levodopa (LD) individually and in combination (Benserazide hydrochloride + LD) (25 μM; 0 hour, 12 hours, 24 hours and 168 hours; SH-SY5Y) treatment inhibit protein aggregation and have the ability to minimise the amyloid-induced cytotoxicity in human neuroblastoma cell line. Benserazide hydrochloride and LD both can act as efficient inhibitors of the formation of cytotoxic HSA aggregates, and the inhibitory effects are more pronounced when both of these drugs are added simultaneously[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[2]

Cell Line: SH-SY5Y cells
Concentration: 25 μM
Incubation Time: 0 hour, 12 hours, 24 hours and 168 hours
Result: Enhanced cell viability, and inhibited the formation of cytotoxic human serum albumin (HSA) aggregates.
In Vivo

Benserazide (5-50 mg/kg; intraperitoneal injection; male Wistar rats) treatment of 6-OHDA-lesioned rats increases exogenous L-DOPA-derived extracellular DA levels, the time to reach the peak DA levels are significantly prolong by Benserazide dose-dependently. The AADC activity in the denervates striatal tissues shows a significant decrease by 10 mg/kg and 50 mg/kg Benserazide. Benserazide reduces the central AADC activity in the striatum of rats with nigrostriatal denervation, which leads to changes in the metabolism of exogenous L-DOPA[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Wistar rats with 6-hydroxydopamine (6-OHDA) (8 Ag/4 Al)[1]
Dosage: 5 mg/kg, 10 mg/kg or 50 mg/kg (Pharmacokinetic study)
Administration: Intraperitoneal injection
Result: Increased in exogenous L-DOPA-derived extracellular DA levels, the time to reach the peak DA levels were significantly prolonged in a dose-dependent fashion. The AADC activity in the denervated striatal tissues showed a significant decreased by 10 mg/kg and 50 mg/kg.
Clinical Trial
Molecular Weight

293.70

Formula

C₁₀H₁₆ClN₃O₅

CAS No.
Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (340.48 mM; Need ultrasonic)

H2O : ≥ 50 mg/mL (170.24 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.4048 mL 17.0242 mL 34.0483 mL
5 mM 0.6810 mL 3.4048 mL 6.8097 mL
10 mM 0.3405 mL 1.7024 mL 3.4048 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one:  PBS

    Solubility: 100 mg/mL (340.48 mM); Clear solution; Need ultrasonic

  • 2.

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (7.08 mM); Clear solution

  • 3.

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (7.08 mM); Clear solution

  • 4.

    Add each solvent one by one:  10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (7.08 mM); Clear solution

*All of the co-solvents are provided by MCE.
References

Purity: 99.41%

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Benserazide hydrochloride
Cat. No.:
HY-B0404A
Quantity:
MCE Japan Authorized Agent: